Q BioMed Announces FDA Approval
Q BioMed Inc. (QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC. IsoTherapeutics is now cleared to manufacture the Company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP.Q BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology Platform Development
Q BioMed Inc., a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform technology asset from Mannin Research Inc.Q BioMed Adds Big Pharma Executive to Board of Directors
Q BioMed Inc., a biotechnology acceleration company, is pleased to welcome Dr. Rick Panicucci as an independent member on its board of Directors.Q BioMed Adds Boston University's Dr. Helen Tager-Flusberg to Advisory Committee
Q BioMed Inc., a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.Q BioMed Inc. Announces Development Partnership with Sphaera Pharma
Q BioMed Inc., a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.Q Biomed Inc. Adds Nuclear Medicine Industry Veteran to Commercialization Team
Q BioMed Inc, a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team.Q Biomed Inc Announces Two New Members to Its Scientific Advisory Board
Q BioMed Inc., a biotechnology acceleration company is pleased to announce the appointment of Dr. Amy Ripka and Dr. Rick Panicucci to its board of scientific advisors.Q Biomed Inc. Completes Final Closing on $4,000,000 Funding
Q BioMed Inc., has closed on its final tranche of the $4,000,000 funding announced on November 30th, 2016. The company received $1,500,000 less fees on the final closing bringing the total gross funds received to date to $4MM.Q Biomed Joins with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology to Develop Liver Cancer Chemotherapeutic
Q BioMed, Inc. has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.Q BioMed Provides Update on Corporate Developments
Q BioMed Inc., a biotechnology acceleration company is pleased to report on its asset acquisition and an update on corporate development.